Table 1

Baseline characteristics of patients

(n=29)
Age
Median (range)70 (43–86)
Gender—no (%)
Male22 (75.9)
Female7 (24.1)
Race—no (%)
White25 (86.2)
Hispanic3 (10.3)
Asian/Pacific Islander1 (3.4)
Immunocompromised—no (%)3 (10.3)
ECOG performance status—no (%)
010 (34.5)
115 (51.7)
24 (13.8)
Primary tumor site—no (%)
Head/neck16 (55.2)
Trunk8 (27.6)
Extremity5 (17.2)
Extent of disease—no (%)
Locally advanced20 (69.0)
Metastatic9 (31.0)
Clinicopathological features—no (%)
Recurrent tumor18 (62.1)
Poorly defined borders13 (44.8)
Perineural invasion6 (20.7)
Aggressive histology—no (%)19 (65.5)
Basosquamous8 (27.6)
Morpheaform4 (13.8)
Mixed3 (10.3)
Micronodular2 (6.9)
Other2 (6.9)
Anatomic site of metastases—no (%)
Lung7 (24.1)
Lymph node6 (20.7)
Bone4 (13.8)
Liver1 (3.4)
Prior therapy—no (%)
Surgery21 (72.4)
Radiation18 (62.1)
Hedgehog inhibitor24 (82.8)
Reason for discontinuing prior hedgehog inhibitor therapy—no (%)
Progression of disease18 (75.0)
Adverse events3 (12.5)
Other3 (12.5)
  • ECOG, Eastern Cooperative Oncology Group.